Advantages of the αeolus platform

• All the advantages of a DPI
  The popularity of Dry Powder Inhalers is increasing due to the benefits that this type of technology has over other forms of inhaler. Benefits include:

   

  • Ease of use – inherently breath-actuated, DPIs avoid the user coordination requirements that frequently prevent users of pMDIS (“puffer” inhalers) from getting their full dose
  • Stability – dry-powders are inherently more stable than liquid suspensions
  • Sustainability – as a propellant-free dosage form, DPIs have the potential to have a lower Global Warming Potential than existing pMDI technologies
  • High payload potential – DPIs do not have the same limits on active dry payload as pMDIs

• High and consistent dose delivery
  αeolus uses novel technologies to generate a high Fine Particle Fraction (FPF), which brings two significant benefits:

   

  • More drug delivered to the lung (where it needs to be), and less deposited in the mouth and throat (causing unpleasant side-effects) unlike traditional DPIs
  • The amount of drug delivered is largely independent of the inhalation effort, meaning consistent dosing for the same user and between users

   

  For the ‘how’, see our article on ‘The Energy-Efficiency Curve’.

• Blister based
  αeolus uses standard cold-formed unit-dose blisters as the primary drug container, providing excellent and well-understood protection against moisture ingress and avoiding issues associated with capsules or reservoir-based devices.
• Platform technology
  αeolus is a platform technology that forms the ‘core’ of a range of potential inhaler embodiments. Fundamentally, all DPIs built on the αeolus platform can have identical performance, meaning that you can conduct studies using a low-cost form of αeolus device before committing to a higher-cost or bespoke device without jeopardising your insights and results from previous trials.
• Supports clinical trial success
  There are important advantages for any company undertaking a clinical study with devices that feature αeolus:

   

  • The dose delivered to the lungs will be more consistent for each patient as well as across the patient group, meaning the chance of success is higher
  • The core αeolus technology is a platform and transferable to different inhaler designs, meaning initial testing can be conducted with a low-cost device before moving to a bespoke device with identical performance

   

  Cambridge Healthcare Innovations offer hope of a long-awaited step change in the field of inhalers, without the need for pharmaceutical companies to conduct years of research in either developing a device with sufficient performance for their formulation, or engineering their formulation to work with sub-optimal devices.